Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis

Figure 4

Kaplan-Meier for overall survival excluding patients with Primary Disease Progression (n = 820) according to RTDI binary cuts. A: 95% (median OS: 112 weeks (95% CI [97-136]) for RTDI ≥ 95% vs. 104 weeks (95% CI [91-129]) for RTDI < 95%. B: 90% (The median OS was 118 weeks (95% CI [103-138]) for RTDI ≥ 90% vs. 103 weeks (95% CI [86-120]) for RTDI < 90%.); C: 85% (The median OS was 118 weeks (95% CI [103-136]) for RTDI ≥ 85% vs. 96 weeks (95% CI [83-119]) for RTDI < 85%). D: 80% (The median OS was 116 weeks (95% CI [103-133]) for RTDI ≥ 80% vs. 96 weeks (95% CI [77-124]) for RTDI < 80%.) E: 75% (The median OS was 113 weeks (95% CI [103-133]) for RTDI ≥ 75% vs. 93 weeks (95% CI [76-119]) for RTDI < 75%.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us